Anavex Life Sciences Corp (AVXL)

[nidan7500]

Anyone see/understand how multiple regulatory body approvals works/benefits/slows/accelerates the open market sales picture for A2-73 (for example?). Since it seems clear that FDA would have to be suicidal (due to multiple time internally established tangles and conflicts) to lead the parade for AVXL CNS treatment approvals. Then, which national-body or reginal interests stands to benefit the most by approval use-scripting-sales for their populations of clinical users?

A. Who will be first? When? Why ?
B. How does FDA unscrew itself from Amyloid thesis CNS disease past w/a straight face and move on? (CAN THEY) (THEN WHAT?)

What other top management regulatory issues are in the way of moving FWD right now???

What will be AVXL-Dr.M. and staff's next move to drive the above issues??